APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis

Clinical trial NCT01960348 · COMPLETED

Trial details

NCT number: NCT01960348
Sponsor: Alnylam Pharmaceuticals
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

TTR-mediated Amyloidosis Amyloidosis, Hereditary Amyloid Neuropathies, Familial Familial Amyloid Polyneuropathies Amyloid Neuropathies Amyloidosis, Hereditary, Transthyretin-Related

Start date: 2013-11-01
Primary completion: 2017-08-01
Enrollment: 225

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.